AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market

AstraZeneca's biologics unit MedImmune is continuing to solidify its domination of the market for products to prevent serious respiratory syncytial virus disease in high-risk infants with a formal reply to FDA's "complete response" letter for its investigational product motavizumab